SCHEMBL17520239

SCHEMBL17520239

CCc1cnccc1-c1cccc(Br)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNC P24863 1/20 0.48
CDK8 P49336 1/20 0.48
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
GABRG2 P18507 3/20 0.40
GABRB3 P28472 3/20 0.40
GABRA5 P31644 3/20 0.40
GABRA3 P34903 3/20 0.40
GABRA1 P14867 2/20 0.40
DAPK3 O43293 1/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
CYP19A1 P11511 1/20 0.40
GCGR P47871 1/20 0.39
MAPK14 Q16539 1/20 0.39
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20371450 0.81 SLC22A12 (0.53) CCNCCDK8DAPK3DGAT2GPBAR1
SCHEMBL11652269 0.81 MEN1 (0.51) CCNCCDK8KDM4EALDH1A1MEN1
SCHEMBL14927060 0.80 CCNC (0.51) CCNCCDK8GPBAR1
SCHEMBL18162725 0.79 MEN1 (0.44) CCNCCDK8KDM4EALDH1A1LMNA
SCHEMBL9434701 0.78 EGFR (0.40) KDM4EALDH1A1LMNAHPGDMEN1
Bromide SCHEMBL29018736 0.78 CCNC (0.50) CCNCCDK8GPBAR1
SCHEMBL29354816 0.78 ALDH1A1 (0.43) KDM4EALDH1A1LMNAHPGDMEN1
SCHEMBL4919575 0.78 ALDH1A1 (0.43) KDM4EALDH1A1LMNAHPGDMEN1
SCHEMBL22489864 0.77 CCNC (0.44) CCNCCDK8LRRK2GPBAR1
SCHEMBL2662370 0.77 LMNA (0.46) CCNCCDK8KDM4ELMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016201370-A1 COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-12-15 WO disclosed
WO-2016073956-A1 EZH2 INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-05-12 WO disclosed
WO-2016073903-A1 USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-05-12 WO disclosed
WO-2016022970-A1 DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-02-11 WO disclosed
WO-2016022902-A1 DIAZEPANE DERIVATIVES AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2016-02-11 WO disclosed